New Venturetec reported earnings results for the year ended September 30, 2016. For the year, the company reported a loss of USD 60,649,374 or USD 12.09 per share, compared to a gain of USD 15,105,459 or USD 3.00 per share in the fiscal year 2014/15. The net asset value per share decreased from USD 12.94 to USD 0.94 which equals -92.7% during the reporting period. The main reason for the loss was the decrease of the quoted share price of Osiris Therapeutics from USD 18.47 per share to USD 4.96 per share or-73.2% and the decrease of the traded share price of Myriad Genetics from USD 37.48 to USD 20.58 or -45.1%.